30 years of nanobodies - an ongoing success story of small binders in biological research

J Cell Sci. 2023 Nov 1;136(21):jcs261395. doi: 10.1242/jcs.261395. Epub 2023 Nov 8.

Abstract

A milestone in the field of recombinant binding molecules was achieved 30 years ago with the discovery of single-domain antibodies from which antigen-binding variable domains, better known as nanobodies (Nbs), can be derived. Being only one tenth the size of conventional antibodies, Nbs feature high affinity and specificity, while being highly stable and soluble. In addition, they display accessibility to cryptic sites, low off-target accumulation and deep tissue penetration. Efficient selection methods, such as (semi-)synthetic/naïve or immunized cDNA libraries and display technologies, have facilitated the isolation of Nbs against diverse targets, and their single-gene format enables easy functionalization and high-yield production. This Review highlights recent advances in Nb applications in various areas of biological research, including structural biology, proteomics and high-resolution and in vivo imaging. In addition, we provide insights into intracellular applications of Nbs, such as live-cell imaging, biosensors and targeted protein degradation.

Keywords: Affinity capture; Crystallization; Intracellular protein manipulation; Live-cell imaging; Nanobodies.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Single-Domain Antibodies* / metabolism

Substances

  • Single-Domain Antibodies